Pre-made Narsoplimab benchmark antibody ( Whole mAb, anti-MASP2 therapeutic antibody, Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-366

Pre-Made Narsoplimab biosimilar, Whole mAb, Anti-MASP2 Antibody: Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Narsoplimab is the company's lead inhibitor of mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-366-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Narsoplimab biosimilar, Whole mAb, Anti-MASP2 Antibody: Anti-MAP-2/MAP19/MASP-2/MASP1P1/sMAP therapeutic antibody
INN Name Narsoplimab
TargetMASP2
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCLambda
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesOmeros
Conditions Approvedna
Conditions ActiveHaemolytic uraemic syndrome;IgA nephropathy;Immediate hypersensitivity;Thrombotic microangiopathies;Glomerulonephritis;Lupus nephritis;Membranous glomerulonephritis
Conditions DiscontinuedStroke;Wet age-related macular degeneration
Development Techna